PE20120834A1 - Derivados de furopirimidindiona como moduladores de trpa1 - Google Patents

Derivados de furopirimidindiona como moduladores de trpa1

Info

Publication number
PE20120834A1
PE20120834A1 PE2011001704A PE2011001704A PE20120834A1 PE 20120834 A1 PE20120834 A1 PE 20120834A1 PE 2011001704 A PE2011001704 A PE 2011001704A PE 2011001704 A PE2011001704 A PE 2011001704A PE 20120834 A1 PE20120834 A1 PE 20120834A1
Authority
PE
Peru
Prior art keywords
furopyrimidindiona
derivatives
tetrahydrofide
cra
dioxo
Prior art date
Application number
PE2011001704A
Other languages
English (en)
Inventor
Abraham Thomas
Indranil Mukhopadhyay
Sachin Sundarlal Chaudhari
Nishap Parag Patil
Neelima Khairatkar-Joshi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PE20120834A1 publication Critical patent/PE20120834A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON CADA UNO H, ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS; R3 ES H, ALQUILO, ALQUENILO, CICLOALQUILALQUILO, ENTRE OTROS; Z1 Y Z2 SON CADA UNO O, CRa, CON LA CONDICION DE QUE UNO ES O Y EL OTRO CRa; L ES UN LIGADOR DE PREFERENCIA -CH2-; U ES ARILO SUSTITUIDO O NO, TIAZOL, PIRAZOL, IMIDAZOL, OXAZOL, ENTRE OTROS; V ES H, CIANO, NITRO, HALOGENO, HALOALCOXILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[4-(4-TRIFLUOROMETILFENOXI)FENIL]-2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROFURO[2,3-d]PIRIMIDIN-5-IL)ACETAMIDA; N-(4,6-DIFLUORO-1,3-BENZOTIAZOL-2-IL)-2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROFURO[2,3-d]PIRIMIDIN-5-IL)ACETAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE TRPA 1 UTILES EN EL TRATAMIENTO DE DOLOR, NEURALGIA, MIGRANA, NEUROPATIAS, CIATICA, ENTRE OTROS
PE2011001704A 2009-03-23 2010-03-22 Derivados de furopirimidindiona como moduladores de trpa1 PE20120834A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2213MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12

Publications (1)

Publication Number Publication Date
PE20120834A1 true PE20120834A1 (es) 2012-07-25

Family

ID=42780205

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001704A PE20120834A1 (es) 2009-03-23 2010-03-22 Derivados de furopirimidindiona como moduladores de trpa1
PE2011001705A PE20120775A1 (es) 2009-03-23 2010-03-23 Derivados de tienopirimidindiona como moduladores de trpa1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001705A PE20120775A1 (es) 2009-03-23 2010-03-23 Derivados de tienopirimidindiona como moduladores de trpa1

Country Status (23)

Country Link
US (4) US20120178766A1 (es)
EP (3) EP2411395B1 (es)
JP (2) JP2012521406A (es)
KR (2) KR20110128898A (es)
CN (3) CN102361874A (es)
AP (1) AP2948A (es)
AU (2) AU2010227225A1 (es)
BR (2) BRPI1013705A2 (es)
CA (2) CA2756535A1 (es)
DK (3) DK2411395T3 (es)
EA (2) EA201190138A1 (es)
ES (3) ES2424341T3 (es)
HK (2) HK1166074A1 (es)
HU (1) HUE024538T2 (es)
IL (2) IL215175A (es)
MX (1) MX2011009822A (es)
PE (2) PE20120834A1 (es)
PL (3) PL2411395T3 (es)
PT (3) PT2411395E (es)
SG (4) SG184767A1 (es)
SI (3) SI2411395T1 (es)
WO (2) WO2010109329A1 (es)
ZA (2) ZA201107650B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
PL2411393T3 (pl) 2009-03-23 2014-06-30 Glenmark Pharmaceuticals Sa Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1
MY159059A (en) 2010-12-20 2016-12-15 Glenmark Pharmaceuticals Sa 2-amino-4-arylthiazole compounds as trpa1 antagonists
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
MX2013014679A (es) * 2011-06-13 2014-07-14 Glenmark Pharmaceuticals Sa Tratamiento de trastornos respiratorios usando antagonistas de trpa1.
WO2012176143A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
US20140364445A1 (en) * 2011-12-05 2014-12-11 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
IN2014MN02467A (es) * 2012-06-08 2015-07-10 Glenmark Pharmaceuticals Sa
CN104822653B (zh) 2012-10-01 2017-03-08 奥赖恩公司 N‑丙‑2‑炔基甲酰胺衍生物及其作为trpa1拮抗剂的用途
BR112015030341A2 (pt) 2013-06-20 2017-07-25 Glenmark Pharmaceuticals Sa formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
MX2016004741A (es) * 2013-10-15 2016-07-26 Glenmark Pharmaceuticals Sa Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
EP3180337B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CN109310683A (zh) * 2016-04-07 2019-02-05 杜克大学 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂
EP3592739A1 (en) * 2017-03-07 2020-01-15 H. Hoffnabb-La Roche Ag Oxadiazole transient receptor potential channel inhibitors
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE69912618T2 (de) * 1998-08-28 2004-10-28 Astrazeneca Ab NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
DE60332475D1 (de) * 2002-10-30 2010-06-17 Vertex Pharma Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
US7465581B2 (en) 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CA2536313A1 (en) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
US20090062258A1 (en) 2005-02-03 2009-03-05 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
AU2006278592A1 (en) * 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
WO2007054474A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives useful in treatment of trpv1 related disorders
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
TWI423819B (zh) 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
CN104825457B (zh) * 2007-06-22 2019-11-19 伊莱利利公司 用于治疗病症的方法和组合物
CN101711413B (zh) * 2007-06-25 2013-09-04 桑迪士克科技股份有限公司 具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
DK2411397T3 (da) 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
JP5629324B2 (ja) 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ601143A (en) 2010-01-12 2014-10-31 Ab Science Thiazole and oxazole kinase inhibitors
TWI421250B (zh) 2010-07-13 2014-01-01 Novartis Ag 衍生物及其用於治療神經性疾病之用途

Also Published As

Publication number Publication date
BRPI1009381B1 (pt) 2020-04-14
US20120295924A1 (en) 2012-11-22
SG184767A1 (en) 2012-10-30
SI2634191T1 (sl) 2015-04-30
CA2756535A1 (en) 2010-09-30
EP2411395B1 (en) 2013-05-29
CN103755720A (zh) 2014-04-30
ZA201107650B (en) 2012-07-25
AU2010227230B2 (en) 2015-11-26
BRPI1009381A2 (pt) 2016-06-21
EP2411396A2 (en) 2012-02-01
EP2634191B1 (en) 2014-12-24
HUE024538T2 (hu) 2016-01-28
AU2010227225A2 (en) 2011-10-06
EA201190138A1 (ru) 2013-05-30
IL215175A0 (en) 2011-12-29
AU2010227225A1 (en) 2011-09-15
SI2411395T1 (sl) 2013-07-31
US8987278B2 (en) 2015-03-24
ES2424341T3 (es) 2013-10-01
US9474758B2 (en) 2016-10-25
US20120178766A1 (en) 2012-07-12
CN103755720B (zh) 2016-07-06
ES2532386T3 (es) 2015-03-26
BRPI1013705A2 (pt) 2016-04-05
US20130289054A1 (en) 2013-10-31
KR20120004422A (ko) 2012-01-12
SI2411396T1 (sl) 2013-07-31
BRPI1009381B8 (pt) 2021-05-25
CN102361874A (zh) 2012-02-22
AU2010227230A2 (en) 2011-10-27
DK2411396T3 (da) 2013-08-05
IL215177A (en) 2014-01-30
AP2948A (en) 2014-07-31
PT2411396E (pt) 2013-06-06
US20150150876A1 (en) 2015-06-04
HK1166073A1 (en) 2012-10-19
IL215177A0 (en) 2011-12-29
WO2010109334A2 (en) 2010-09-30
KR20110128898A (ko) 2011-11-30
AP2011005889A0 (en) 2011-10-31
CA2756536C (en) 2015-10-06
JP2012521407A (ja) 2012-09-13
PE20120775A1 (es) 2012-06-27
CA2756536A1 (en) 2010-09-30
JP5612070B2 (ja) 2014-10-22
ZA201107649B (en) 2012-07-25
DK2411395T3 (da) 2013-08-05
PT2634191E (pt) 2015-03-04
DK2634191T3 (en) 2015-03-23
US8507503B2 (en) 2013-08-13
SG174398A1 (en) 2011-10-28
SG174404A1 (en) 2011-10-28
KR101524337B1 (ko) 2015-05-29
IL215175A (en) 2014-01-30
PL2411395T3 (pl) 2013-10-31
SG184769A1 (en) 2012-10-30
HK1166074A1 (en) 2012-10-19
ES2424342T3 (es) 2013-10-01
PT2411395E (pt) 2013-06-06
CN102361877A (zh) 2012-02-22
WO2010109334A3 (en) 2010-11-25
JP2012521406A (ja) 2012-09-13
CN102361877B (zh) 2014-05-07
AU2010227230A1 (en) 2011-09-22
PL2634191T3 (pl) 2015-06-30
EP2411395A1 (en) 2012-02-01
MX2011009822A (es) 2012-01-25
EA201190139A1 (ru) 2012-03-30
EA022029B1 (ru) 2015-10-30
WO2010109329A1 (en) 2010-09-30
PL2411396T3 (pl) 2013-10-31
EP2411396B1 (en) 2013-05-29
EP2634191A1 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20090641A1 (es) Amidas heterociclicas
PE20100737A1 (es) Nuevos compuestos
AR054799A1 (es) Derivados de oxindol
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20171645A1 (es) Derivados de heterociclos biciclicos condensados sustituidos con 2-(het)arilo como agentes para combatir parasitos
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20091321A1 (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica
PE20091095A1 (es) Moduladores de gamma secretasa
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
PE20091444A1 (es) Derivados de isoxazolo-pirazina

Legal Events

Date Code Title Description
FD Application declared void or lapsed